(secondQuint)Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer.

 OBJECTIVES: I.

 Assess the antitumor activity of danazol in patients with advanced or recurrent endometrial cancer.

 II.

 Determine the nature and toxicity of danazol in these patients.

 OUTLINE: Patients receive oral danazol 4 times per day for at least 4 weeks.

 Patients with partial response, complete response, or stable disease continue treatment in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

 PROJECTED ACCRUAL: A total of 23-56 patients will be accrued for this study within 26 months.

.

 Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer@highlight

RATIONALE: Hormone therapy may be an effective treatment for endometrial cancer.

 PURPOSE: Phase II trial to study the effectiveness of danazol in treating patients with advanced or recurrent endometrial cancer.

